Establishment of a UPLC-MS/MS Method for Studying the Effect of Salt-Processing on Tissue Distribution of Twelve Major Bioactive Components of Qing’e Pills in Rats

Table 4

The extract recoveries and matrix effect of 12 compounds in rat kidney (n = 6).

Compound	Concentrations (ng/mL)	Extract recovery (%)	RSD (%)	Matrix effect (%)	RSD (%)
Psoralen	5	87.98 ± 6.41	7.28	94.20 ± 4.04	4.29
	500	87.93 ± 4.88	5.56	93.42 ± 8.77	9.39
	800	85.67 ± 5.13	5.99	90.85 ± 5.01	5.51
Isopsoralen	5	88.74 ± 2.73	3.08	93.86 ± 5.75	6.12
	500	88.60 ± 2.99	3.38	91.92 ± 2.66	2.90
	800	88.99 ± 1.58	1.78	92.27 ± 2.95	3.19
Psoralenoside	12.50	89.79 ± 4.10	4.56	92.47 ± 2.24	2.42
	1000	89.19 ± 0.94	1.06	94.75 ± 0.56	0.59
	1600	85.34 ± 1.60	1.87	94.75 ± 0.71	0.75
Bavachin	2.50	87.75 ± 3.23	3.69	93.05 ± 2.06	2.22
	250	88.84 ± 1.47	1.66	93.96 ± 3.26	3.47
	400	89.48 ± 0.96	1.07	93.99 ± 1.15	1.22
Isobavachin	0.25	88.02 ± 1.93	2.19	93.64 ± 3.13	3.34
	125	85.59 ± 3.12	3.64	95.01 ± 3.74	3.93
	200	88.69 ± 3.70	4.17	96.38 ± 2.98	3.09
Bavachalcone	1.25	89.55 ± 1.41	1.58	94.90 ± 0.60	0.64
	50	88.41 ± 1.30	1.46	91.19 ± 2.13	2.34
	80	89.15 ± 1.08	1.21	91.98 ± 1.05	1.14
Isobavachalcone	2.50	88.16 ± 0.91	1.03	92.54 ± 1.10	1.19
	250	89.37 ± 0.98	1.10	94.42 ± 1.04	1.10
	400	89.85 ± 0.76	0.85	94.79 ± 0.78	0.82
Pinoresinol diglucoside	2.50	84.65 ± 4.01	4.74	94.00 ± 3.43	3.65
	50	88.75 ± 1.09	1.23	94.73 ± 1.00	1.06
	80	88.27 ± 1.42	1.61	93.94 ± 1.45	1.55
Geniposidic acid	2.50	88.32 ± 2.99	3.39	93.39 ± 2.75	2.94
	1000	89.17 ± 0.71	0.79	94.66 ± 1.53	1.62
	1600	90.84 ± 0.97	1.06	98.15 ± 1.89	1.93
Psoralidin	2.50	88.35 ± 2.61	2.95	94.17 ± 1.91	2.03
	500	88.98 ± 1.01	1.14	94.74 ± 1.24	1.31
	800	87.13 ± 3.36	3.85	95.96 ± 0.35	0.36
Psoralen	2.50	88.45 ± 2.73	3.09	93.34 ± 2.25	2.41
	500	81.59 ± 4.60	5.63	88.22 ± 7.30	8.27
	800	85.60 ± 4.27	4.99	94.39 ± 1.09	1.16
Isopsoralen	2.50	89.51 ± 2.68	2.99	91.45 ± 2.94	3.22
	250	87.68 ± 3.15	3.59	94.97 ± 3.76	3.96
	400	85.32 ± 6.02	7.05	93.64 ± 1.86	1.99